![ESMOBreast24_Poster_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-breast-cancer-2024/coverage/esmobreast24_poster_01/19164016-1-eng-GB/esmobreast24_poster_01_i770.jpg)
Atezolizumab plus sacituzumab govitecan show encouraging activity in inoperable triple-negative breast cancer
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours